FDA Accepts for Filing Intellipharmaceutics' ANDA for Generic Seroquel XR (IPCI)

Intellipharmaceutics International IPCItoday announced the U.S. Food and Drug Administration has accepted for filing its abbreviated new drug application for a generic version of Seroquel XR. Seroquel XR is an oral psychotropic agent indicated for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Sales of Seroquel XR in the U.S. were approximately $823 million in 2010.